# Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis

> **NCT05089565** · — · COMPLETED · sponsor: **Northwestern University** · enrollment: 101 (actual)

## Conditions studied

- Sarcoidosis
- SARS-CoV2 Infection
- Vaccine Response Impaired

## Interventions

- **DIAGNOSTIC_TEST:** Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation

## Key facts

- **NCT ID:** NCT05089565
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2023-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05089565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05089565, "Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05089565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*